Updated Experience of

Publication/Presentation Date

8-1-2021

Abstract

BACKGROUND: Despite safety communications from the Food and Drug Administration (FDA) regarding the outbreak of

METHODS: We retrospectively reviewed confirmed cases of MCI that were managed at Mayo Clinic sites (Arizona, Florida, and Minnesota) from 09/2015 to 01/2021. Clinical histories including prior cardiovascular surgery were recorded. Diagnostic workup including ophthalmologic examination, imaging, and laboratory testing was reviewed. Treatment and survival outcomes on follow-up were obtained.

RESULTS: Twelve patients with MCI were included. All patients had aortic valve or graft replacement. Five patients had their surgical procedures following the 10/15/2015 FDA safety communication. The mean time from surgery to symptom onset (range) was 32 (13-73) months. Ten of 11 patients who underwent ophthalmologic examination had chorioretinal abnormalities. Three patients who underwent microbial cell-free deoxyribonucleic acid sequencing tested positive for

CONCLUSIONS: MCI continues to occur despite the FDA communications. Incorporation of ophthalmologic examination and use of advanced tools may improve MCI diagnosis. The mortality in these patients is high even with aggressive surgical/medical management.

Volume

8

Issue

8

First Page

348

Last Page

348

ISSN

2328-8957

Disciplines

Medicine and Health Sciences

PubMedID

34377729

Department(s)

Department of Medicine, Cardiology Division

Document Type

Article

Share

COinS